Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics company, is pleased to announce that the Company has been granted a key patent by the United States Patent and Trademark Office (USPTO). This newly issued patent adds to the expanding foundational patent estate held by Evox and further reinforces the Company’s leading position within the field of exosome-mediated RNA drug delivery.
The recently issued US patent (U.S. Patent 10,704,047) provides broad coverage for pharmaceutical compositions comprising exosomes containing nucleic acid-based therapeutics, such as RNAi agents and antisense oligonucleotides, which have been loaded by electroporation.
Dr Per Lundin, Chief Operating Officer of Evox, commented: “We are very pleased to have been granted another foundational patent, reflecting our scientific and IP leadership in the exosome therapeutics space. This is another significant development that gives Evox dominant coverage in exosome-mediated RNA delivery, as well as key steps in the manufacturing process.”
Dr Antonin de Fougerolles, Chief Executive Officer of Evox, added: “Over the past decade, Evox has built an unrivalled global patent estate with broad and deep coverage of the key applications of exosome therapeutics. This recent grant represents a great addition of our IP position and further reinforces Evox’s leading position as the partner of choice in the field of exosome therapeutics.”
For enquiries, please contact:
Dr Antonin de Fougerolles, Chief Executive Officer, Evox Therapeutics Ltd +44 (0) 1865 819140
Simon Conway / Natalie Garland-Collins, FTI Consulting +44 (0) 203 727 1000
About Evox Therapeutics
Evox Therapeutics is a privately held, Oxford-based biotechnology company focused on harnessing and engineering the natural delivery capabilities of extracellular vesicles, known as exosomes, to develop an entirely new class of biotherapeutics. Backed by Oxford Sciences Innovation and supported by a comprehensive intellectual property portfolio, Evox’s mission is to positively impact human health by creating novel exosome-based biotherapeutics for the treatment of various severe diseases with limited options for patients and their families. Evox has created substantial proprietary technology to modify exosomes using various molecular engineering, drug loading, and targeting strategies to facilitate targeted drug delivery to organs of interest, including the brain and the central nervous system. Exosome-based drugs have the potential to address some of the limitations of protein, antibody and nucleic acid-based therapies by enabling delivery to cells and tissues that are currently out of reach using other drug delivery technologies, and Evox is leading the development within this emerging therapeutic space.